Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Aripiprazole microspheres
- Development stage
- Unknown
- Lead developer
- Livzon Pharmaceutical
- Modality
- Small Molecules
- Administration
- Intramuscular
01
Overview
Aripiprazole microspheres (LZMT05) is a long-acting injectable (LAI) formulation of the atypical antipsychotic aripiprazole, developed by Livzon Pharmaceutical Group (specifically through its subsidiary Livzon Microsphere Technology). The drug is formulated as biodegradable polymer-based microspheres designed for intramuscular injection, providing sustained release of the active ingredient over approximately one month. Aripiprazole functions as a partial agonist at dopamine D2 and D3 receptors and serotonin 5-HT1A receptors, while acting as an antagonist at serotonin 5-HT2A receptors. This formulation is primarily indicated for the treatment of schizophrenia in adults, aiming to improve medication adherence and provide stable therapeutic plasma concentrations compared to daily oral dosing.
- Other names
- 注射用阿立哌唑微球Aripiprazole long-acting injectable (microspheres)
02
Targets
HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))HTR2A (Serotonin receptor 5-HT2A)HTR2C (5-hydroxytryptamine 2C receptor)HTR7 (5-hydroxytryptamine receptor 7)ADRA1A (α1A)DRD2 (Dopamine D2 Receptor)DRD3 (Dopamine receptor D3)DRD4 (Dopamine D4 Receptor)HRH1 (Histamine H1 Receptor)
Beyond the preview
Go deeper on Aripiprazole microspheres.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Aripiprazole microspheres.